Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.62 |
| ▸ | CA2 | P00918 | 2/20 | 0.62 |
| ▸ | CA9 | Q16790 | 2/20 | 0.62 |
| ▸ | CA12 | O43570 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | FAAH | O00519 | 1/20 | 0.45 |
| ▸ | MGLL | Q99685 | 1/20 | 0.45 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9308514 | 0.82 | POLB (0.77) | CA1CA2CA9CA12POLB | |
| SCHEMBL28548456 | 0.81 | CA12 (0.59) | CA1CA2CA9CA12POLB | |
| SCHEMBL40711 | 0.79 | KMT2A (0.59) | CA1CA2CA9CA12POLB | |
| SCHEMBL19002513 | 0.79 | ALDH1A1 (0.66) | CA1CA2CA9CA12POLB | |
| SCHEMBL5767794 | 0.79 | CA12 (0.58) | CA1CA2CA9CA12POLB | |
| SCHEMBL19049363 | 0.79 | CA12 (0.53) | CA1CA2CA9CA12POLB | |
| SCHEMBL290791 | 0.78 | POLB (0.70) | CA1CA2CA9CA12POLB | |
| SCHEMBL5311390 | 0.77 | GSK3A (0.69) | CA1CA2CA9CA12POLB | |
| SCHEMBL6607455 | 0.77 | CA12 (0.47) | CA1CA2CA9CA12POLB | |
| SCHEMBL15704375 | 0.77 | MGLL (0.78) | CA1CA2CA9ALDH1A1FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6531604-B2 | Useful as medicines having an osteogenesis promoting effect and chondrogensis promoting effect. | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-03-11 | — | — | US | disclosed |
| US-20020128308-A1 | Benzothiepine derivatives, their production and use | YASUMA TSUNEO (JP) | 2002-09-12 | — | — | US | disclosed |
| US-6355672-B1 | BONE DISORDERS; CENTRAL NERVOUS SYSTEM DISORDERS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-03-12 | — | — | US | disclosed |
| EP-1103552-A1 | BENZOTHIEPIN DERIVATIVES, PROCESS FOR THE PREPARATION OF THE SAME AND USES THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2001-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128308-A1 | Benzothiepine derivatives, their production and use | APP, BMP1, BACE1 | CA1 1369/4885CA2 1053/4885CA9 1955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.